BankPlus Trust Department Makes New Investment in Encompass Health Co. (NYSE:EHC)

BankPlus Trust Department bought a new position in shares of Encompass Health Co. (NYSE:EHC) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 936 shares of the company’s stock, valued at approximately $86,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. TD Private Client Wealth LLC raised its holdings in shares of Encompass Health by 2,870.0% during the third quarter. TD Private Client Wealth LLC now owns 7,336 shares of the company’s stock worth $709,000 after purchasing an additional 7,089 shares during the period. Los Angeles Capital Management LLC raised its holdings in shares of Encompass Health by 532.4% during the third quarter. Los Angeles Capital Management LLC now owns 50,290 shares of the company’s stock worth $4,860,000 after purchasing an additional 42,338 shares during the period. Pathstone Holdings LLC increased its holdings in shares of Encompass Health by 54.5% in the 3rd quarter. Pathstone Holdings LLC now owns 21,022 shares of the company’s stock worth $2,032,000 after acquiring an additional 7,412 shares during the period. Meeder Asset Management Inc. increased its holdings in shares of Encompass Health by 43.8% in the 3rd quarter. Meeder Asset Management Inc. now owns 66,405 shares of the company’s stock worth $6,417,000 after acquiring an additional 20,242 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of Encompass Health by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,673,610 shares of the company’s stock worth $161,781,000 after acquiring an additional 20,547 shares during the period. 97.25% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CAO Andrew L. Price sold 5,042 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $98.29, for a total transaction of $495,578.18. Following the completion of the transaction, the chief accounting officer now owns 69,164 shares in the company, valued at approximately $6,798,129.56. This trade represents a 6.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 2.10% of the company’s stock.

Encompass Health Stock Up 1.4 %

Encompass Health stock opened at $98.86 on Tuesday. The stock has a market cap of $9.96 billion, a price-to-earnings ratio of 22.17, a PEG ratio of 2.31 and a beta of 0.90. The company has a current ratio of 1.05, a quick ratio of 1.04 and a debt-to-equity ratio of 0.84. The company’s 50-day moving average price is $96.01 and its two-hundred day moving average price is $96.05. Encompass Health Co. has a 52 week low of $73.68 and a 52 week high of $104.55.

Encompass Health (NYSE:EHC) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. On average, analysts expect that Encompass Health Co. will post 4.8 EPS for the current fiscal year.

Encompass Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 17th. Stockholders of record on Tuesday, April 1st will be given a dividend of $0.17 per share. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.68 annualized dividend and a dividend yield of 0.69%. Encompass Health’s dividend payout ratio (DPR) is 15.25%.

Analysts Set New Price Targets

A number of analysts recently weighed in on EHC shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $110.00 price objective on shares of Encompass Health in a report on Tuesday, February 11th. William Blair reaffirmed an “outperform” rating on shares of Encompass Health in a report on Friday, February 7th. KeyCorp increased their price objective on shares of Encompass Health from $117.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Truist Financial reaffirmed a “buy” rating and issued a $116.00 price objective (up previously from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. Finally, Barclays increased their price objective on shares of Encompass Health from $116.00 to $118.00 and gave the stock an “overweight” rating in a report on Friday, February 7th. Ten research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $107.67.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.